ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Hanyang, Seoul, KOR:

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor (NIRVANA-R)

survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor....

Enrolling
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Drug: Niraparib-Bevacizumab

Phase 2

Yonsei University
Yonsei University

Seoul, Korea, Republic of

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 125 other locations

adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with...

Enrolling
Ovarian Cancer Stage IV
Ovarian Cancer by FIGO Stage
Drug: Paclitaxel
Drug: Bevacizumab

Phase 1, Phase 2

CanariaBio

Seoul, Korea, Republic of and 5 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Seoul, Korea, Republic of and 93 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 176 other locations

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer...

Enrolling
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim

Phase 2, Phase 3

Sutro Biopharma

Seoul, Korea, Republic of and 37 other locations

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have prog...

Enrolling
Ovarian Cancer
Drug Related Neoplasm/Cancer
Drug: chemotherapy
Procedure: secondary cytoreductive surgery

Phase 2

Korea University

Seoul, Korea, Republic of

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

Phase 3

Mural Oncology

Seoul, Korea, Republic of and 131 other locations

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...

Enrolling
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Pegylated liposomal doxorubicin
Drug: Paclitaxel

Phase 1

K-Group Beta

Seoul, Korea, Republic of and 22 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems